Mucosis develops RVS vaccine
Thursday 24 March 2016
- Life Cooperative
The human respiratory syncytial virus (RSV) is a major cause of seasonal epidemics of severe lower respiratory tract disease. Worldwide an estimated 64 million RSV infections occur annually, resulting in the death of approximately 160,000 individuals. While RSV attacks all age groups, the most severe disease occurs in (i) the elderly, (ii) patients with chronic lung disease, (iii) persons with impaired immunity and (iv) very young infants (≤2 years of age). There is currently no vaccine available to prevent disease caused by RSV.
Our candidate vaccine SynGEM® is an RSV subunit vaccine based on the validated bacterium-like-particle (BLP) based Mimopath® technology carrying F proteins. The BLP technology allows presentation of stabile native trimeric F proteins that elicit locally secreted IgA in the mucosal layers and a balanced Th1/Th2-type of systemic immune responses that are protective. It will be developed at first instance for the elderly, adults at risk and children, and potentially at a later stage for infants.
Focus areasLife Cooperative
Wednesday 6 February 2019
High presence talent at Meet&Greets 2019
Wednesday 30 January 2019
LIFE Cooperative: ‘An important ecosystem in the field of ..
Tuesday 15 January 2019
InnoCore Pharmaceuticals will develop contraceptive micron..
Tuesday 4 December 2018
Welcome to new start up EV Biotech
Monday 5 November 2018
Worldwide market at LIFE Cooperatives feet
Monday 3 September 2018
Lode Holding: initiator, participant and part of the Campu..
Tuesday 28 August 2018
A goldmine in Groningen: business in biobanking
Thursday 23 August 2018
Lode Holding & MercachemSyncom at the start of Campus ..
Tuesday 7 August 2018
AGILeBiotics further develops novel antibiotics
Monday 30 July 2018
Worldwide cooperation agreement InnoCore Pharmaceuticals a..